The Climate is Changing for Metered-Dose Inhalers and Action is Needed

References

• SteinSW, ThielCG. The history of therapeutic aerosols; a chronological review. J Aerosol Med Pulmon Drug Deliv. 2017;30:20–41. doi:10.1089/jamp.2016.1297
   PubMed Web of Science ®Google Scholar
• PritchardJN. The environmental impact of propellants – what now? In: Drug Delivery to the Lungs. 10-13 Bristol, UK: The Aerosol Society; 2019.
   Google Scholar
• Intergovernmental Panel on Climate Change Climate Change 2013: The Physical Science Basis. Contribution of Working Group I to the Fifth Assessment Report of the Intergovernmental Panel on Climate Change. StockerTF, QinD, PlattnerG-K, et al., Editors. Cambridge, United Kingdom: Cambridge University Press; 2013 1535 pp
   Google Scholar
• World Meteorological Organization. WMO Statement on the state of the global climate in 2018. Available from: https://library.wmo.int/doc_num.php?explnum_id=5789. Accessed July 17, 2020.
   Google Scholar
• United National Environment Programme. Assessment report of the technology and economic assessment panel; 2014 Available from: https://ozone.unep.org/sites/default/files/2019-05/TEAP_Assessment_report_2014.pdf. Accessed July 17, 2020.
   Google Scholar
• European Commission. Regulation (EU) No 517/2014 of the European Parliament and of the Council of 16 April 2014 on Fluorinated Greenhouse Gases and Repealing Regulation (EC) No 842/2006 Text with EEA Relevance. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R0842&qid=1594982827385&from=EN. Accessed July 17, 2020.
   Google Scholar
• European Environment Agency. Emissions and supply of fluorinated greenhouse gases in Europe. Available from: https://www.eea.europa.eu/data-and-maps/indicators/emissions-and-consumption-of-fluorinated-2/assessment-2. Accessed July 17, 2020.
   Google Scholar
• United Nations Environment Program. The Kigali Amendment to the Montreal Protocol: HFC Phase-Down. OzonAction Fact Sheet OZFS/16/11_1. Paris, France: United Nations Environmental Program; 2016.
   Google Scholar
• United Nations Technical and Economic Assessment Panel. Decision XXVII/4 task force update report; further information on alternatives to ozone depleting substances Volume I. Nairobi, Kenya; United Nations Environment Programme; 2016 Available from: https://ozone.unep.org/sites/default/files/2019-05/TEAP_TFXXVII-4_Report_September2016.pdf. Accessed July 17, 2020.
   Google Scholar
• Sustainable development Unit, National Health Service, United Kingdom. Available from: https://www.sduhealth.org.uk/nhs%20long%20term%20plan/carbon-reduction/anaesthetics-and-inhalers.aspx. AccessedJuly 17, 2020.
   Google Scholar
• UsmaniOS, ScullionJ, KeeleyD. Our planet or our patients-is the sky the limit for inhaler choice? Lancet Respir Med. 2019;7:11–13. doi:10.1016/S2213-2600(18)30497-130553845
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical and Healthcare Excellence. Patient decision aid; inhalers for Asthma; 2019 Available from: https://www.nice.org.uk/guidance/ng80/resources/inhalers-for-asthma-patient-decision-aid-pdf-6727144573. Accessed July 17, 2020.
   Google Scholar
• KeeleyD, ScullionJE, Usmani O. Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers. Eur Respir J. 2020;55:2001122. doi:10.1183/13993003.00048-202032461340
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Understanding our 2017 value chain carbon footprint. Available from: https://www.gsk.com/en-gb/responsibility/environment/carbon. Accessed July 17, 2020.
   Google Scholar
• PanigoneS, SandriF, FerriR, et al. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Resp Res. 2020;7:e000571. doi:10.1136/bmjresp-2020-000571
   PubMed Web of Science ®Google Scholar
• PartridgeMR. Green respiratory healthcare: need for proportionality. Thorax. 2020;75:369. doi:10.1136/thoraxjnl-2019-21431532094153
   PubMed Web of Science ®Google Scholar
• JeswaniHK, AzapagicA. Life cycle environmental impacts of inhalers. J Cleaner Prod. 2019;237:117733. doi:10.1016/j.jclepro.2019.117733
   Web of Science ®Google Scholar
• AstraZeneca. Investing in a sustainable future for patients with respiratory disease. Available from: https://www.astrazeneca.com/media-centre/articles/2020/investing-in-a-sustainable-future-for-patients-with-respiratory-disease.html. Accessed July 17, 2020.
   Google Scholar
• FarmaceuticiC. Chiesi outlines €350 million investment and announces first carbon minimal pressurised metered dose inhaler (pMDI) for Asthma and COPD 04/ 12/2019. Available from: https://www.chiesi.com/en/chiesi-outlines-350-million-investment-and-announces-first-carbon-minimal-pressurised-metered-dose-inhaler-pmdi-for-asthma-and-copd/. Accessed July 17, 2020.
   Google Scholar
• ViswanathanR. Why Starbucks, Disney, and the EU are all shunning plastic straws. Available from: https://www.vox.com/2018/6/25/17488336/plastic-straw-ban-ocean-pollution. Accessed July 17, 2020.
   Google Scholar
• WilkinsonAJK, BragginsR, SteinbachI, et al. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019;9:e028763. doi:10.1136/bmjopen-2018-028763
   PubMed Web of Science ®Google Scholar
• PritchardJN. What are meaningful device improvements for patients, providers and payers In: DalbyRN, ByronPR, PeartJ, et al. editors. Respiratory Drug Delivery. River Grove, IL: Davis Healthcare International;2014;1: 217–228.
   Google Scholar
• NormansellR, KewKM, MathioudakisAG. Interventions to improve inhaler technique for people with asthma. Cochrane Database Systematic Rev. 2017;3 Art. No.: CD012286
   PubMedGoogle Scholar
• ThomasM, PriceD, ChrystynH, et al. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med. 2009;9:1–10. doi:10.1186/1471-2466-9-119121204
   PubMedGoogle Scholar
• BjermerL. The importance of continuity in inhaler device choice for asthma and chronic obstructive pulmonary disease. Respiration. 2014;88:346–352. doi:10.1159/00036377125195762
   PubMed Web of Science ®Google Scholar
• LevyM, DekhuijzenPNR, BarnesPJ, et al. Inhaler technique: facts and fantasies. A view from the Aerosol Drug Management Improvement Team (ADMIT). Primary Care Respir Med. 2016;26:16017. doi:10.1038/npjpcrm.2016.17
   PubMed Web of Science ®Google Scholar
• MurakiM, GoseK, HanadaS, et al. Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler? Drug Deliv. 2017;24:1395–1400. doi:10.1080/10717544.2017.137893728929816
   PubMed Web of Science ®Google Scholar
• LavoriniF, CorriganCJ, BarnesPJ, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105:1099–1103. doi:10.1016/j.rmed.2011.03.01221489771
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020 report. Available from: https://ginasthma.org/gina-reports/. Accessed July 17, 2020.
   Google Scholar
• Global initiative for chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2020 Report. Available from: https://goldcopd.org/gold-reports/. Accessed July 17, 2020..
   Google Scholar
• BoniniM, UsmaniO. The importance of inhaler devices in the treatment of COPD. COPD Res Pract. 2015;1–9.
   Google Scholar
• LiangC-Y, ChenY-J, SheuS-M, et al. Misuse of inhalers among COPD patients in a community hospital in Taiwan. Int J COPD. 2018;13:1309–1316. doi:10.2147/COPD.S158864
   Google Scholar
• MahlerDA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thoracic Soc. 2017;14:1103–1107. doi:10.1513/AnnalsATS.201702-156PS
   PubMed Web of Science ®Google Scholar
• LohCH, PetersSP, LovingsTM, et al. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14:1305–1311. doi:10.1513/AnnalsATS.201611-903OC28406710
   PubMed Web of Science ®Google Scholar
• JarvisS, IndPW, ShinerRJ. Inhaled therapy in elderly COPD patients; Time for re-evaluation? Age Ageing. 2007;36:213–218. doi:10.1093/ageing/afl17417267450
   PubMed Web of Science ®Google Scholar
• JenkinsD, JohalJ, MahonJ. P228 Analysis of the potential clinical impact of an environmentally driven transition from pressurised metered dose inhalers (pMDIs) to dry powder inhalers (DPIs). Thorax. 2019;74:A213-A214.
   Google Scholar
• British Lung Foundation. Available from: https://statistics.blf.org.uk/copd. Accessed July 17, 2020.
   Google Scholar
• SullivanPW, GhushchyanVH, CampbellJD, et al. Measuring the cost of poor asthma control and exacerbations. J Asthma. 2017;54:24–31. doi:10.1080/02770903.2016.119443027286240
   PubMed Web of Science ®Google Scholar
• Ur RehmanA, HassaliMAA, MuhammadSA, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2019. doi:10.1080/14737167.2020.1678385
   Web of Science ®Google Scholar
• Center for Disease Control National Center for Health Statistics. Fast stats. Available from: https://www.cdc.gov/nchs/fastats. Accessed 717, 2020.
   Google Scholar
• NurmagambetovT, KuwaharaR, GarbeP. The Economic Burden of Asthma in the United States, 2008–2013. Ann Amer Thoracic Soc. 2018;15:348–356. doi:10.1513/AnnalsATS.201703-259OC
   PubMed Web of Science ®Google Scholar
• Solvay Special Chemicals. HFA propellants for medical use. Available from: https://www.solvay.us/en/binaries/35442-237443.pdf. Accessed July 17, 2020.
   Google Scholar
• FrielM, inventor; Aer Beatha Ltd assignee: canister and valve. United States Patent Application US20190315560A1. 2019 10 17.
   Google Scholar
• GoldbergT. Strength to strength. World Aerosols. 2019;32–33.
   Google Scholar
• LindleyAA, NoakesTJ. Consideration of hydrofluoroolefins (HFOs) as potential candidate medical propellants. Mexichem Fluor, 2010 Available from: https://www.zephex.co.uk/wp-content/uploads/2020/01/HFOs-as-candidate-medical-propellants.pdf. Accessed July 17, 2020
   Google Scholar
• CorrS, NoakesT. Pressurized metered dose inhaler propellants: going forward In: DalbyRN, ByronPR, PeartJ, et al. editors. Respiratory Drug Delivery. River Grove, IL: DHI Publishing;2017;2: 255–258.
   Google Scholar
• CorrS, NoakesTJ, inventors; Mexichem Amanco Holding SA de CV assignee. Compositions comprising salbutamol sulphate. United States Patent US9114164B2. 2015 8 25
   Google Scholar
• Koura. ‘Green’ medical propellant receives FDA approval to proceed to clinical trials. Available from: https://www.prnewswire.com/news-releases/green-medical-propellant-receives-fda-approval-to-proceed-to-clinical-trials-300998598.html. Accessed July 17, 2020.
   Google Scholar
• VanceC, SwalwellC, McIntyreIM. Deaths involving 1,1-difluoroethane at the San Diego County medical examiner’s office. J Anal Toxicol. 2012;36:626–633. doi:10.1093/jat/bks07423034927
   PubMed Web of Science ®Google Scholar
• ToonRC, PreedyEC, ProkopovichP. Formulating drugs for inhalers and stability issues. Eurasian Chem Tech J. 2012;14:271–286. doi:10.18321/ectj124
   Google Scholar
• TaylorG, WarrenS, Tran C inventors; Cardiff Scintigraphics Ltd assignee. Pressurized metered dose inhalers and method of manufacture. United States Patent 9981092B2. 2018 5 29.
   Google Scholar
• HowlettD. Balancing the needs of patients, regulators, and industry to satisfy the global demand for inhaled products In: DalbyRN, PeartJ, YoungPM, et al. editors. Respiratory Drug Delivery Asia 2018. River Grove: IL; DHI Publishing; 2018:119–128.
   Google Scholar
• PritchardJN. F-gas regulations and beyond: clinical and economic factors that will drive propellant transition In: DalbyRN, ByronPR, PeartJ, et al. editors. Respiratory Drug Delivery . River Grove, IL: DHI Publishing;2020;1: 183–193.
   Google Scholar